iBio to Present New Preclinical Data on Its Activin E Antibody at Two Upcoming Scientific Conferences, ObesityWeek® and PEGS Europe 2025
iBio, Inc. (IBIO)
NASDAQ:AMEX Investor Relations:
ir.ibioinc.com
Company Research
Source: GlobeNewswire
SAN DIEGO, Oct. 21, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator of precision antibody therapies, today announced that Cory Schwartz, Ph.D., Director of Research and Early Development at iBio, will deliver an oral presentation at ObesityWeek 2025 November 4-7 in Atlanta. In addition, Martin Brenner, DVM, Ph.D., Chief Executive Officer and Chief Scientific Officer of iBio, will deliver an oral presentation at PEGS Europe 2025 November 11–13 in Lisbon. “We are excited to share additional data from the non-human primates study of our Activin E antibody, IBIO-610, which continues to support its potential as a differentiated approach to the treatment of obesity,” said Dr. Brenner. “These findings add to a growing body of research that inhibiting Activin E signaling could deliver fat-selective weight loss, support long-term weight maintenance, and enhance the benefits of GLP-1 therapies. These data suggest IBIO-610 could help overcome key limitations of curre
Show less
Read more
Impact Snapshot
Event Time:
IBIO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IBIO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IBIO alerts
High impacting iBio, Inc. news events
Weekly update
A roundup of the hottest topics
IBIO
News
- iBio to Participate in the 8th Annual Evercore Healthcare ConferenceGlobeNewswire
- iBio (NASDAQ:IBIO) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=IBIO&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> from MarketBeat
- iBio Reports Q1 Fiscal Year 2026 Financial Results and Provides Corporate Update [Yahoo! Finance]Yahoo! Finance
- iBio Reports Q1 Fiscal Year 2026 Financial Results and Provides Corporate UpdateGlobeNewswire
- iBio Unveils New Non-Human Primate Data on IBIO-610, an Activin E Antibody with Strong Therapeutic Potential for Fat-Selective Weight-Loss and Weight MaintenanceGlobeNewswire
IBIO
Sec Filings
- 12/3/25 - Form SCHEDULE
- 11/24/25 - Form 4
- 11/24/25 - Form 4
- IBIO's page on the SEC website